Literature DB >> 34962522

Contraception Selection, Effectiveness, and Adverse Effects: A Review.

Stephanie Teal1, Alison Edelman2.   

Abstract

IMPORTANCE: Many women spend a substantial proportion of their lives preventing or planning for pregnancy, and approximately 87% of US women use contraception during their lifetime. OBSERVATIONS: Contraceptive effectiveness is determined by a combination of drug or device efficacy, individual fecundability, coital frequency, and user adherence and continuation. In the US, oral contraceptive pills are the most commonly used reversible method of contraception and comprise 21.9% of all contraception in current use. Pregnancy rates of women using oral contraceptives are 4% to 7% per year. Use of long-acting methods, such as intrauterine devices and subdermal implants, has increased substantially, from 6% of all contraceptive users in 2008 to 17.8% in 2016; these methods have failure rates of less than 1% per year. Estrogen-containing methods, such as combined oral contraceptive pills, increase the risk of venous thrombosis from 2 to 10 venous thrombotic events per 10 000 women-years to 7 to 10 venous thrombotic events per 10 000 women-years, whereas progestin-only and nonhormonal methods, such as implants and condoms, are associated with rare serious risks. Hormonal contraceptives can improve medical conditions associated with hormonal changes related to the menstrual cycle, such as acne, endometriosis, and premenstrual dysphoric disorder. Optimal contraceptive selection requires patient and clinician discussion of the patient's tolerance for risk of pregnancy, menstrual bleeding changes, other risks, and personal values and preferences. CONCLUSIONS AND RELEVANCE: Oral contraceptive pills are the most commonly used reversible contraceptives, intrauterine devices and subdermal implants have the highest effectiveness, and progestin-only and nonhormonal methods have the lowest risks. Optimal contraceptive selection incorporates patient values and preferences.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34962522     DOI: 10.1001/jama.2021.21392

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  4 in total

1.  Preliminary side effect profile, safety, and tolerability of hormonal contraception among women receiving opioid-agonist therapy.

Authors:  Heidi S Melbostad; Deborah S Wachtel; Kerstin A Lipke; Gary J Badger; Alexis K Matusiewicz; Catalina N Rey; Lauren K MacAfee; Anne K Dougherty; Sarah H Heil
Journal:  Contraception       Date:  2022-03-11       Impact factor: 3.051

2.  Effect of Surface Interactions on Microsphere Loading in Dissolving Microneedle Patches.

Authors:  Derek Jang; Jie Tang; Steven P Schwendeman; Mark R Prausnitz
Journal:  ACS Appl Mater Interfaces       Date:  2022-06-22       Impact factor: 10.383

Review 3.  Estetrol/Drospirenone: A Review in Oral Contraception.

Authors:  Arnold Lee; Yahiya Y Syed
Journal:  Drugs       Date:  2022-07-04       Impact factor: 11.431

4.  Analysis of Adverse Events and Medical Errors in Long-Term Hormone Treatments for Endometriosis: A Study Based on the US Food and Drug Administration Event Reporting System.

Authors:  Yuxin Zhang; Yiping Zhu; Jing Sun
Journal:  Int J Womens Health       Date:  2022-09-06
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.